Paragon 28, Inc. (FNA)

NYSE: FNA · IEX Real-Time Price · USD
11.76
-0.72 (-5.77%)
Mar 1, 2024, 4:00 PM EST - Market closed
-5.77%
Market Cap 974.03M
Revenue (ttm) 216.39M
Net Income (ttm) -47.84M
Shares Out 82.56M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,145,523
Open 11.32
Previous Close 12.48
Day's Range 11.00 - 11.96
52-Week Range 7.95 - 19.72
Beta 1.05
Analysts Strong Buy
Price Target 23.33 (+98.38%)
Earnings Date Feb 29, 2024

About FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunio... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 15, 2021
Employees 463
Stock Exchange NYSE
Ticker Symbol FNA
Full Company Profile

Financial Performance

In 2023, Paragon 28's revenue was $216.39 million, an increase of 19.30% compared to the previous year's $181.38 million. Losses were -$47.84 million, -28.94% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for FNA stock is "Strong Buy." The 12-month stock price forecast is $23.33, which is an increase of 98.38% from the latest price.

Price Target
$23.33
(98.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...

3 days ago - Business Wire

Paragon 28 to Present at the CG 2024 Musculoskeletal Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

20 days ago - Business Wire

Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...

26 days ago - Business Wire

Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy u...

4 weeks ago - Business Wire

Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System...

4 weeks ago - Business Wire

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis lon...

5 weeks ago - Business Wire

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a...

7 weeks ago - Business Wire

Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape

ENGLEWOOD, Co.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company's position in the ...

2 months ago - Business Wire

Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

2 months ago - Business Wire

Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment...

3 months ago - Business Wire

Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System which was developed to provide for increased strength and stabi...

3 months ago - Business Wire

Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training program making it even more convenient for...

3 months ago - Business Wire

Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announc...

4 months ago - Business Wire

Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...

4 months ago - Business Wire

Paragon 28 to Present at Upcoming Investor Conferences

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

4 months ago - Business Wire

Paragon 28 To Report Third Quarter Financial Results on November 7, 2023

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...

4 months ago - Business Wire

Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for ...

6 months ago - Business Wire

Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

6 months ago - Business Wire

Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...

7 months ago - Business Wire

Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

7 months ago - Business Wire

Paragon 28 To Report Second Quarter Financial Results on August 2, 2023

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report fina...

8 months ago - Business Wire

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy (SMO) Plating and PRESERVE™ SMO Allograft System which were d...

10 months ago - Business Wire

Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reporte...

10 months ago - Business Wire

Paragon 28 to Present at the Bank of America Securities 2023 Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chai...

11 months ago - Business Wire

Paragon 28 Launches Phantom® Metatarsal Shortening System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for...

11 months ago - Business Wire